Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Free Cash Flow: 2017-2025

Historic Free Cash Flow for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to -$111.6 million.

  • Crinetics Pharmaceuticals' Free Cash Flow fell 76.13% to -$111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$354.0 million, marking a year-over-year decrease of 72.19%. This contributed to the annual value of -$229.8 million for FY2024, which is 34.40% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Free Cash Flow is -$111.6 million, which was down 25.30% from -$89.1 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' 5-year Free Cash Flow high stood at -$13.6 million for Q1 2022, and its period low was -$111.6 million during Q3 2025.
  • In the last 3 years, Crinetics Pharmaceuticals' Free Cash Flow had a median value of -$54.2 million in 2024 and averaged -$62.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 32.47% in 2022, then slumped by 198.98% in 2023.
  • Crinetics Pharmaceuticals' Free Cash Flow (Quarterly) stood at -$22.9 million in 2021, then crashed by 54.82% to -$35.5 million in 2022, then fell by 11.19% to -$39.5 million in 2023, then slumped by 61.41% to -$63.7 million in 2024, then slumped by 76.13% to -$111.6 million in 2025.
  • Its Free Cash Flow was -$111.6 million in Q3 2025, compared to -$89.1 million in Q2 2025 and -$89.7 million in Q1 2025.